Patents by Inventor Alexander Knuth

Alexander Knuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy including tumor associated antigen binding antibodies
    Publication number: 20180353603
    Abstract: The present invention relates to a combination therapy including tumor associated antigen binding antibodies.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Inventors: Christoph Esslinger, Alexander Knuth, Martin Treder, Maries van den Broek, Elke Jaeger
  • MAGEA3 BINDING ANTIBODIES
    Publication number: 20140186363
    Abstract: The present invention relates to MAGEA3 binding antibodies.
    Type: Application
    Filed: May 23, 2012
    Publication date: July 3, 2014
    Applicants: UNIVERSITY OF ZURICH, CT ATLANTIC LTD.
    Inventors: Christoph Esslinger, Michael Höcker, Martin Treder, Alexander Knuth, Elke Jaeger
  • MAGEA3 BINDING ANTIBODIES
    Publication number: 20140093514
    Abstract: The present invention relates to MAGEA3 binding antibodies.
    Type: Application
    Filed: May 23, 2012
    Publication date: April 3, 2014
    Applicants: University of Zurich, CT ATLANTIC LTD.
    Inventors: Christoph Esslinger, Michael Höcker, Martin Treder, Alexander Knuth, Elke Jäger
  • COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTIGEN BINDING ANTIBODIES
    Publication number: 20130295091
    Abstract: The present invention relates to a combination therapy including tumor associated antigen binding antibodies.
    Type: Application
    Filed: January 10, 2012
    Publication date: November 7, 2013
    Applicants: University of Zurich, CT ATLANTIC LTD
    Inventors: Christoph Esslinger, Alexander Knuth, Martin Treder, Maries Van Den Broek, Elke Jaeger
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Patent number: 8541202
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: September 24, 2013
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Monoclonal human tumor-specific antibody
    Patent number: 8519106
    Abstract: Provided are novel human tumor-specific antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigen NY-ESO-1. In addition, pharmaceutical compositions comprising such antibodies and mimics thereof in the treatment of tumors are described.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: August 27, 2013
    Assignee: University of Zurich
    Inventors: Christoph Esslinger, Sandra Künzle, Irene Abela, Alfred Zippelius, Dirk Jäger, Alexander Knuth, Roger Nitsch, Holger Moch, Norbert Göbels
  • METHOD FOR INDUCING CELL LYSIS WITH IMMUNOGENIC PORTIONS OF NY-ESO-1 PROTEIN
    Publication number: 20120231035
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: February 24, 2012
    Publication date: September 13, 2012
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Patent number: 8142786
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 27, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 8071717
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: December 6, 2011
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Publication number: 20110182944
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: January 10, 2011
    Publication date: July 28, 2011
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • PROTAMINE/RNA NANOPARTICLES FOR IMMUNOSTIMULATION
    Publication number: 20110123637
    Abstract: The present invention relates to protamine/RNA nanoparticles of defined average size, a pharmaceutical composition containing said nanoparticles and to a method of producing the same. The nanoparticles of the present invention is particularly useful as an immunostimulating medicament with a precise pattern of immunostimulation different from the prior art.
    Type: Application
    Filed: May 26, 2009
    Publication date: May 26, 2011
    Applicant: UNIVERSITAT ZURICH
    Inventors: Steve Pascolo, Alexander Knuth
  • METHOD OF PROVIDING HUMAN TUMOR-SPECIFIC ANTIBODIES
    Publication number: 20110123447
    Abstract: Provided are novel tumor-specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigens and that are obtained from a tumor patient who shows at least partial clinical response or is symptom-free. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of tumors are described.
    Type: Application
    Filed: March 13, 2008
    Publication date: May 26, 2011
    Applicant: UNIVERSITY OF ZURICH
    Inventors: Christoph Esslinger, Sandra Kuenzle, Irene Abela, Roger Nitsch, Holger Moch, Norbert Goebels, Dirk Jaeger, Alfred Zippelius, Alexander Knuth
  • Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
    Patent number: 7888100
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: February 15, 2011
    Assignees: Memorial Sloan-Kettering Cancer Research, Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • MONOCLONAL HUMAN TUMOR-SPECIFIC ANTIBODY
    Publication number: 20100330075
    Abstract: Provided are novel human tumor-specific antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigen NY-ESO-1. In addition, pharmaceutical compositions comprising such antibodies and mimics thereof in the treatment of tumors are described.
    Type: Application
    Filed: March 13, 2008
    Publication date: December 30, 2010
    Inventors: Christoph Esslinger, Sandra Kuenzle, Irene Abela, Alfred Zippelius, Dirk Jaeger, Alexander Knuth, Roger Nitsch, Holger Moch, Norbert Goebels
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Publication number: 20100278850
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Application
    Filed: October 27, 2009
    Publication date: November 4, 2010
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof
    Patent number: 7795409
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: September 14, 2010
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Dirk Jager, Elisabeth Stockert, Barry C. Picker, legal representative, Matthew Scanlan, Cynthia H. Scanlan, legal representative, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 7795379
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: September 14, 2010
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Elke Jager, Dirk Jager, Alexander Knuth
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 7622568
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: November 24, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof
    Publication number: 20090203123
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Application
    Filed: January 30, 2008
    Publication date: August 13, 2009
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen, Barry C. Picker, Cynthia H. Scanlan
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Publication number: 20080177031
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Application
    Filed: November 12, 2007
    Publication date: July 24, 2008
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager